BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16041598)

  • 1. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
    Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A
    Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
    HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
    King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
    J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
    Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
    AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Morse GD; Rosenkranz S; Para MF; Segal Y; Difrancesco R; Adams E; Brizz B; Yarasheski KE; Reichman RC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3373-81. PubMed ID: 16048950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.